Related Experiment Video

Updated: Jun 23, 2026

A High-content Imaging Workflow to Study Grb2 Signaling Complexes by Expression Cloning
10:52

A High-content Imaging Workflow to Study Grb2 Signaling Complexes by Expression Cloning

Published on: October 30, 2012

Development of Grb2 SH2 Domain Signaling Antagonists: A Potential New Class of Antiproliferative Agents

Terrence R Burke

    International Journal of Peptide Research and Therapeutics
    |May 16, 2009
    PubMed

    Insights

    Targeting the Grb2 SH2 domain with novel agents can disrupt protein-tyrosine kinase (PTK) signaling. This approach offers an alternative strategy for treating proliferative diseases and cancers by inhibiting downstream PTK pathways.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Medicinal Chemistry

    Background:

    • Aberrant protein-tyrosine kinase (PTK) signaling drives proliferative diseases, including cancers.
    • Growth factor receptor bound protein 2 (Grb2) is a key mediator of PTK signaling, binding phosphotyrosyl sequences via its SH2 domain.
    • Inhibiting Grb2 SH2 domain interactions presents a therapeutic strategy distinct from direct kinase inhibition.

    Purpose of the Study:

    • To review the development of agents targeting the Grb2 SH2 domain.
    • To explore modifications of peptide-based inhibitors bound to the Grb2 SH2 domain.
    • To discuss strategies for disrupting PTK signaling through Grb2 modulation.

    Main Methods:

    • Utilizing X-ray crystallography of a lead peptide bound to the Grb2 SH2 domain as a starting point.
    • Thematic arrangement of modifications from the N-terminus to the C-terminus of the peptide.
    • Inclusion of a dedicated section on conformational constraint aspects.

    Main Results:

    • Summarizes contributions to developing Grb2 SH2 domain-binding agents.
    • Highlights structure-based design insights for peptide modifications.
    • Demonstrates the potential of targeting Grb2 as an alternative to PTK inhibitors.

    Conclusions:

    • Agents binding the Grb2 SH2 domain can effectively disrupt PTK signaling.
    • Structure-guided peptide modifications offer a viable route for therapeutic development.
    • Targeting Grb2 represents a promising alternative in cancer and proliferative disease treatment.

    More Related Videos

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

    Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

    Published on: July 17, 2020

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    The Retinoblastoma Gene01:20

    The Retinoblastoma Gene

    Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
    The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...